9 04, 2021

New study using TAmiRNAs SARS-CoV-2 Antibody Test (Lateral Flow Method)

2021-09-10T10:47:07+02:00April 9th, 2021|SARS, SARS-CoV-2 Antibody Test|Comments Off on New study using TAmiRNAs SARS-CoV-2 Antibody Test (Lateral Flow Method)

The aims of the study was to determine: (i) SARS-CoV-2 antibody positive employees in Austrian trauma hospitals and rehabilitation facilities, (ii) number of active virus carriers (symptomatic and asymptomatic) during the study (iii) antibody decline in seropositive subjects over a period of around 6 months and (iv) the usefulness of rapid antibody tests for outpatient screening. To find out more about TAmiRNAs SARS-CoV-2 Antibody Test (Lateral Flow Method) click HERE Download the publication HERE

9 04, 2021

TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

2021-04-09T09:00:05+02:00April 9th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, diabetes, microRNAs, microstructure, osteoporosis, Personalized medicine, type 2 diabetes mellitus|Comments Off on TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

TAmiRNA is a key partner in the EU-funded Innovative Training Network FIDELIO, which aims to train the next generation of scientists in tackling the challenges of bone fragility in diabetic patients. The  webinar "MicroRNAs: small RNAs with big potential as biomarkers and drug targets in bone diseases" is a one-hour session hosted by TAmiRNA founder and CEO Dr. Matthias Hackl. He show how microRNAs control gene expression in virtually all human cells and that miRNA expression changes during the onset and progression of (bone) disorders enabling applications as biomarkers and drug targets. He introduce the biological and methodical basics of microRNA research and discuss diagnostic and therapeutic applications of microRNAs in bone disease. [...]

19 01, 2021

Circulating miRNAs in bone health and disease

2021-01-19T10:00:05+01:00January 19th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, microstructure, osteoporosis, Personalized medicine|Comments Off on Circulating miRNAs in bone health and disease

We want to draw your attention to our latest review which appeared in the special issue on miRNAs in Bone Research in Bone. In this review, we summarize important molecular basics of microRNA function and release and provide recommendations for best (pre-)analytical practices and documentation standards for circulating microRNA research required for generating high quality data and ensuring reproducibility of results. We review how the genesis of bone-derived circulating microRNAs via release from osteoblasts and osteoclasts could contribute to the communication between these cells and summarize evidence from clinical research studies that have investigated the clinical utility of microRNAs as biomarkers in musculoskeletal disorders. While previous reviews have mainly focused on diagnosis of primary osteoporosis, we have [...]

24 11, 2020

microRNA-146a controls age-related bone loss

2020-11-24T09:00:05+01:00November 24th, 2020|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, microstructure, osteoporosis, Personalized medicine|Comments Off on microRNA-146a controls age-related bone loss

We want to draw your attention to the latest publication in cooperation with TAmiRNA. The study identifies a novel and unexpected role of miR‐146a in bone homeostasis. miR‐146a increases with age and acts as an epigenetic molecular switch terminating bone accrual, leading to bone loss during aging by downregulating bone anabolic Wnt signaling. Conversely, loss of miR‐146a leads to continuous bone accrual during aging as a result of unrestricted bone anabolism and intact Wnt signaling. Therefore, miR‐146a crucially controls the temporal facet of bone homeostasis. "microRNA-146a controls age-related bone loss" Saferding V, Hofmann M, Brunner JS, et al. Aging Cell. 2020 Nov;19(11):e13244. doi: 10.1111/acel.13244. click here to read the story

6 10, 2020

MedUni Wien “Researcher of the Month” Oktober 2020

2020-10-06T12:12:32+02:00October 6th, 2020|biomarker, Liver disease, microRNAs, Personalized medicine|Comments Off on MedUni Wien “Researcher of the Month” Oktober 2020

We want to congratulate Dr. Patrick Starlinger to his award “Researcher of the Month” for his work in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Click here for more information on TAmiRNA services Click here to read the story

29 05, 2020

microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring

2020-05-29T10:03:50+02:00May 29th, 2020|biomarker, biomarkers, microRNA, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR|Comments Off on microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring

We want to draw your attention to the latest review of TAmiRNA and the King's College London, in Cardiovascular Diabetology. "microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring." Krammer TL, Mayr M & Hackl M. Int. J. Mol. Sci. 2020, 21(10), 3477; doi.org/10.3390/ijms21103477 In this review, we explain the secretion of miRNAs upon platelet activation and discuss the potential use of platelet-related miRNAs as biomarkers for CVD and antiplatelet therapy monitoring, but also highlight remaining gaps in our knowledge and uncertainties regarding clinical utility. click here to read the story

13 01, 2020

New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

2020-01-13T09:00:05+01:00January 13th, 2020|biomarker, biomarkers, clopidogrel, diabetes, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR, type 2 diabetes mellitus|Comments Off on New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

We want to draw your attention to the latest publication of the King's College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response in type-2 diabetics with cardiovascular disease. "Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels." Parker WAE, Schulte C, Bawari T, et al. Cardiovasc Diabetol. 2020 Jan 7;19(1):3. doi: 10.1186/s12933-019-0981-3. click here to read the story

18 11, 2019

MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.

2019-12-10T11:19:14+01:00November 18th, 2019|biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, osteomiR, osteoporosis, Personalized medicine|Comments Off on MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.

We want to draw your attention to the latest publication of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in AUVA Research Center, in cooperation with TAmiRNA GmbH, in Bone. "MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis." Kocijan R, Weigl M, Skalicky S, et al. Bone 2019 Volume 131, February 2020, 115104. https://doi.org/10.1016/j.bone.2019.115104 Take the chance and download the paper

7 11, 2019

Serum microRNA as novel biomarkers for osteoporotic vertebral fractures.

2020-01-10T10:32:08+01:00November 7th, 2019|biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, osteomiR, osteoporosis, Personalized medicine|2 Comments

We want to draw your attention to the latest publication of the Department of Oncology and Metabolism, University of Sheffield, United Kingdom, in cooperation with TAmiRNA GmbH, in Bone. "Serum microRNA as novel biomarkers for osteoporotic vertebral fractures." Zarecki P, Hackl M, Grillari J, et al. Bone 2019 Oct 24:115105. doi: 10.1016/j.bone.2019.115105. Specific circulating miRNAs reflect the presence of osteoporotic vertebral fractures in postmenopausal women. They are unlikely to reflect low BMD, and more likely changes in bone quality or fracture healing. Take the chance and download this paper by clicking here

5 11, 2019

Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

2019-12-10T12:04:11+01:00November 5th, 2019|biomarker, biomarkers, drug development, drug discovery, LMD, microRNAs, Personalized medicine, safety, Vivomicx|Comments Off on Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

We want to draw your attention to the latest publication with our partner Vivomicx. Together we have developed a combination of laser microdissection (LMD) and high quality qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. Our new approch allows to: Discover differential expression patterns between “healthy” and “diseased” tissues on the cellular level; [...]